ORBAX DIN 02237713
Health Canada record
| Active ingredient(s) | ORBIFLOXACIN 22.7 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 13-May-1998 |
| Current status date | 12-Feb-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Intervet Canada Corp. — licence 100147, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ORBIFLOXACIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02237714 | ORBAX | INTERVET CANADA CORP | Tablet | ORBIFLOXACIN 68 MG | Cancelled Post Market |
| 02237712 | ORBAX | INTERVET CANADA CORP | Tablet | ORBIFLOXACIN 5.7 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 10673 | 2009-10-16 | New Drug Submission (NDS) | Change in Ownership |
| 6875 | 1998-04-06 | New Drug Submission (NDS) |
International API supply for ORBIFLOXACIN
0 active FDA Drug Master Files.
Request a quote for ORBAX